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Abstract
Background: Retinoids, through their cognate nuclear receptors, exert potent effects on cell growth, differentiation
and apoptosis, and have significant promise for cancer therapy and chemoprevention. These ligands can
determine the ultimate fate of target cells by stimulating or repressing gene expression directly, or indirectly
through crosstalking with other signal transducers.
Results: Using different breast cancer cell models, we show here that depending on the cellular context
retinoids can signal either towards cell death or cell survival. Indeed, retinoids can induce the expression of pro-
apoptotic (i.e. TRAIL, TNF-Related Apoptosis-Inducing Ligand, Apo2L/TNFSF10) and anti-apoptotic (i.e. cIAP2,
inhibitor of apoptosis protein-2) genes. Promoter mapping, gel retardation and chromatin immunoprecipitation
assays revealed that retinoids induce the expression of this gene mainly through crosstalk with NF-kappaB.
Supporting this crosstalk, the activation of NF-kappaB by retinoids in T47D cells antagonizes the apoptosis
triggered by the chemotherapeutic drugs etoposide, camptothecin or doxorubicin. Notably apoptosis induced
by death ligands (i.e. TRAIL or antiFAS) is not antagonized by retinoids. That knockdown of cIAP2 expression by
small interfering RNA does not alter the inhibition of etoposide-induced apoptosis by retinoids in T47D cells
reveals that stimulation of cIAP2 expression is not the cause of their anti-apoptotic action. However, ectopic
overexpression of a NF-kappaB repressor increases apoptosis by retinoids moderately and abrogates almost
completely the retinoid-dependent inhibition of etoposide-induced apoptosis. Our data exclude cIAP2 and
suggest that retinoids target other regulator(s) of the NF-kappaB signaling pathway to induce resistance to
etoposide on certain breast cancer cells.
Conclusions: This study shows an important role for the NF-kappaB pathway in retinoic acid signaling and
retinoic acid-mediated resistance to cancer therapy-mediated apoptosis in breast cancer cells, independently of
cIAP2. Our data support the use of NF-kappaB pathway activation as a marker for screening that will help to
develop novel retinoids, or retinoid-based combination therapies with improved efficacy.
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Background
The search for alternatives to, and adjuvants for che-
motherapy of breast cancer to prolong survival after the
development of chemoresistance or during chemother-
apy constitutes an area of intensive research. In this
respect the concept of “cancer differentiation therapy”
has emerged as an approach that intends to force a
tumor cell to acquire a less aggressive differentiated
phenotype, concomitant with growth inhibition and ulti-
mately to induce cell death upon terminal differentia-
tion. It has been reported that retinoids exert cell-
differentiating effects in a variety of cancer cells includ-
ing breast cancer. Retinoids, derivatives of vitamin A,
are ligands of the retinoid receptor subclass of the
nuclear receptor superfamily, which comprises three
retinoic acid receptors (RARa, -b, and -g) and three reti-
noid-X-receptors (RXRa, -b, and -g) which form RAR/
RXR heterodimers that are believed to correspond to
the in vivo mediators of the ligand-induced signaling
and regulate a plethora of direct and indirect gene regu-
latory programs [1]. Retinoids regulate important biolo-
gical processes, such as embryo development, control
and maintenance of organ homeostasis, and at the cellu-
lar level growth, differentiation and death [2,3]. These
properties make retinoids promising agents in cancer
therapy and chemoprevention [4]. Particularly, all-trans
retinoic acid (atRA) is the prototypic “cancer differentia-
tion therapy” of human acute promyelocytic leukemia
(APL) that combined with anthracyclins cures 70-80% of
patients [5]. Several groups have reported that retinoid
analogs with agonistic or antagonistic activity can inhibit
the growth [6-9], induce apoptosis [10,11] or cause dif-
ferentiation of breast cancer cell lines [12,13]. Other
groups have noted the capacity of retinoids to inhibit
mammary carcinogenesis in animal models [14-16]. Pre-
vious studies suggest that retinoids inhibit cell growth
interfering with growth factor signaling pathways
[17,18].
The mammalian inhibitor of apoptosis proteins (IAPs),
also known as baculovirus IAP repeat (BIR)-containing
proteins (BIRCs), are evolutionary conserved proteins
defined by their structural similarity. They share one to
three copies of a well-conserved domain of about 70
aminoacids, named BIR. The first IAP was identified in
baculovirus by its capacity to mediate host cell viability
during infection [19,20]. Accordingly, members of this
family particularly cellular IAPs (cIAP1 and cIAP2) and
the X-chromosome-linked IAP (XIAP) have been shown
to be able to protect or delay cell death in response to
apoptotic stimuli when overexpressed [20]. IAPs have
been demonstrated to inhibit cell death by directly
repressing the proapoptotic activity of a family of
cysteine proteases, caspases, as well as targeting
proapoptotic components, such as Smac/DIABLO, for
ubiquitin degradation [21-23]. IAP-deficient mice,
although developing normally, revealed the importance
of these proteins in survival, proliferation and some dif-
ferentiation processes. Thus, NAIP, cIAP2 and XIAP
have been shown to support survival of neurons [24],
cardiomyocytes [25] or macrophages [26] under stress
conditions. On the other hand, IAP proteins are highly
expressed in many human malignancies and play a role
in promoting tumorigenesis through inhibition of cell
death and cooperation with other signaling pathways
associated with malignancies [27,28]. As such, cIAP1/2
were originally identified as TNFR2-associated proteins
[29]. Furthermore, cIAP1/2 and the closely related XIAP
are targets of NF-B signaling pathway [30-32]. The
inducible transcription factor NF-B plays an important
role in numerous biological processes, such as prolifera-
tion and differentiation of many different systems,
including neuronal cells, mammalian skin, myoblast,
osteoclast, and the innate and adaptative immune sys-
tems [33-36]. Furthermore, NF-B-deficient mice and
cells suggest an important role for this transcription fac-
tor in cell survival [37,38] and sensitivity of cancers to
chemotherapy [39,40]. Based on the observation that
inhibition of the inducible transcription factor NF-B,
augments apoptosis mediated by TNF and other stimuli,
it has long been claimed that upregulation of cIAP1/2,
as NF-B-target genes, is responsible for resistance to
cell death induced by TNF and other stimuli [41].
Here, we report that retinoic acid-induced differentia-
tion and apoptosis is accompanied by induction of pro-
survival and pro-apoptotic gene expression programs in
breast cancer cells. In studying the retinoid-activated
survival gene programs we have put particular emphasis
on the role of retinoid-induced NF-B/cIAP2 signaling
pathway(s) on the sensitivity of breast cancer cells
towards chemotherapy. By comparing different breast
cancer cell lines, we found that pretreatment with reti-
noic acid can antagonize chemotherapy-induced cell
death in a cell- dependent manner, which correlates
with the activation of NF-B/cIAP2 signaling pathway
(s). Our data exclude cIAP2 and suggest that other regu-
lator(s) of the NF-B signaling pathway are targeted by
retinoic acid to confer resistance to chemotherapy-
induced cell death.
Results
9-cis-retinoic acid induces either differentiation or cell
death in breast cancer cells in a cell-context dependent
manner
It is well established that the inhibition of breast cancer
cell proliferation by retinoids is accomplished by block-
ing cell cycle progression in the G1 phase. In order to
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find out whether there is a possible contribution of cell
death to the antiproliferative effect of retinoids on breast
cancer cells, we used a sensitive assay that measures the
release of DNA fragments into the cytoplasm of cells.
To maximally activate the RAR-RXR heterodimer, we
used the pan-RAR and RXR agonist 9-cis-retinoic acid
(9-cis-RA) to establish cell death kinetics. As shown in
Fig. 1A-B, the treatment with 9-cis-RA at a pharmacolo-
gical concentration of 10-6 M is able to induce apoptosis
in a cell context-specific manner. Indeed, while 9-cis-RA
treatment does not significantly affect viability of T47D
cells, it is able to induce apoptosis in the breast cancer
cell line H3396. Induction of apoptosis by 9-cis-RA in
this cell line requires RAR since treatment with a pan-
RAR-antagonist, BMS493, blocks retinoid mediated
apoptosis (Fig. 1C). That this block is partial may indi-
cate a possible contribution of alternative rexinoid-
induced death pathways which have been previously
reported [42]. In these cells, mitochondrial membrane
depolarization - a key event in apoptosis - is also
induced by 9-cis-RA or by the RAR-pan-agonist all-
trans retinoic acid (atRA). As shown in Fig. 1D, 9-cis-
RA treatment clearly increases the number of cells pre-
senting a diminished mitochondrial membrane potential
in a time-dependent manner, and causes the release of
the apoptogenic factors cytochrome c and SMAC/DIA-
BLO from the mitochondria to the cytosol (Fig. 1E).
Also, 9-cis-RA activates caspases 8 and 9 and the clea-
vage of a caspase-3 substrate, PARP, as assessed by wes-
tern blot in H3396 cells. When H3396 cells were treated
with TRAIL as positive control for the extrinsic death
pathway, both caspase-8 and caspase-9 were activated
and led to PARP cleavage (Fig. 1F). Together, these data
show that retinoid-induced cell death in H3396 cells
involves a crosstalk between the extrinsic and intrinsic
death pathways.
In contrast to H3396, T47D cell growth was inhibited
without loss of viability after 6 days of 1 μM 9-cis-RA
Figure 1 Retinoic acid promotes either differentiation or cell death of breast cancer cells in a cell-context dependent manner. (A) T47D
and H3396 cells were treated with 9-cis-retinoic acid (9-cis-RA) for the indicated time and analyzed for the presence of DNA fragments in their
cytosol as a measurement of cell death. Y-axis refers to the enrichment of histone complexed DNA fragments (mono- and oligonucleosomes) in
the cytoplasm of apoptotic cells. The values represent the mean ± SD of three different experiments performed in triplicate. (B) T47D and H3396
cells were treated with 9-cis-RA for 6 days. Cell death was determined by FACS analysis after staining with propidium iodide as described in
“Materials and Methods”. The values represent the mean ± SD of three different experiments performed in duplicate. (C) H3396 cells were
treated with 9-cis-RA and the RAR-antagonist BMS493, as indicated, and analyzed as described in (A). (D) H3396 cells were analyzed by flow
cytometry to assess the population of cells with lower mitochondria membrane potential following all-trans retinoic acid (atRA) or 9-cis-RA
treatment for the indicated time. The values represent the mean ± SD of three different experiments performed in duplicate. (E) Release of
mitochondrial proteins to the cytosol was analyzed by western blotting after subcellular fractionation of H3396 cells treated with 9-cis-RA for the
indicated time. (F) Effect of 9-cis-RA treatment on the cleavage of caspase-8 (casp-8), caspase-9 (casp-9) and PARP assessed by western blotting
in H3396 cells. (G) Oil-red O staining of T47D cells untreated or treated with 1 μM 9-cis-RA for 72 h. The images shown are from one
representative experiment performed three times with similar results.
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treatment (Fig. 1A-B). Rather than inducing apoptosis,
9-cis-RA-treated T47D cells showed an increase in lipid
droplet accumulation in the cytoplasm, demonstrated by
Oil Red O staining and microscopic visualization, indi-
cating differentiation of this cell line. T47D cells treated
with 9-cis-RA look enlarged and the lipid droplets are
disposed like a red perinuclear ring (Fig. 1G).
9-cis-RA induces the expression of cIAP2 in breast cancer
cells in a cell context-dependent manner
In order to understand the mechanisms underlying the
differential effects of retinoic acid on breast cancer cells,
we treated several breast cancer cell lines for different
times with 9-cis-RA and analyzed by RNase protection
assay the gene expression levels of different key players
in cell death and survival. Among the different proapop-
totic genes analyzed, we observed significant upregula-
tion of TRAIL and FAS mRNAs by 9-cis-RA in H3396
cells (Fig. 2A, left panel). In T47D cells, we did not
observe a significant change of FAS but TRAIL messen-
ger was upregulated at 6, 9 and 12 days (Fig. 2B, left
panel). Additionally, we analyzed the expression of dif-
ferent members of the BCL2 family, as well as some
members of the apoptosis-inhibitor proteins, IAPs. We
did not observe significant changes in mRNA expression
of the antiapoptotic BCL2 family members tested in
either H3396 or T47D cells (data not shown). However,
cIAP2, a known target of NF-B, was strongly induced
by 9-cis-RA in T47D but not in H3396 cells (Fig. 2A-B,
right panels). We found that induction of cIAP2 gene
expression by 9-cis-RA is not restricted to T47D cells,
since 9-cis-RA was also able to induce cIAP2 in ZR-75-
1 and SK-BR-3 breast cancer cell lines (Fig. 2C). At the
protein level, 9-cis-RA induced cIAP2 in T47D but not
in H3396 cells (Fig. 2D). Induction of cIAP2 gene
expression is a reversible process, since removal of 9-
cis-RA from cell culture media caused a time-dependent
reduction of cIAP2 gene expression, reaching near-basal
levels after 9 days (Fig. 2E). All together, these data
show that 9-cis-RA can induce in a cell context-depen-
dent manner pro-survival and pro-apoptotic gene pro-
grams in breast cancer cells.
9-cis-RA activates cIAP2 transcription through NF-B
response elements and induces in vivo recruitment of p65
and RAR to the cIAP2 promoter
Transient transfection in SK-BR-3 cells of a chimeric
luciferase reporter gene driven by the cIAP2 promoter
demonstrated that a 1.4-kilobase sequence upstream of
the transcription initiation site contains retinoic acid-
inducible elements. Previously the presence of a gluco-
corticoid response element (at position -514), four
Nuclear Factor of Activated T cells (NFAT) binding
sites (at positions -1086, -821, -354 and -301), three
potential binding sites for Activator Protein-1 (AP1) (at
positions -294, -233 and -220), two Interferon Response
Elements (IRF-E) (at positions -475 and -130) and three
NF-B binding sites (at positions -210, -197 and -147)
in the proximal promoter of the cIAP2 gene have been
predicted [31] but sequence analysis did not show the
presence of consensus retinoic-acid response elements
(RAREs) that could mediate stimulation by 9-cis-RA
(Fig. 3A). Promoter mapping initially narrowed the reti-
noic acid responsive sequence down to 174 base pairs
(bp), which in addition to the TATA box, contains an
Interferon Response Element and the NF-B site 3. This
promoter fragment showed a 2-fold 9-cis-RA inducibil-
ity, similar to that found with -200-cIAP2-Luc construct,
which contains an additional NF-B site. However, the
induction by 9-cis-RA of the -247-cIAP2-Luc construct,
which contains three NF-B sites and two AP1 sites,
was significantly higher (about 9-fold), suggesting a
potential role of (some of) these elements in the stimu-
lation by the retinoid. No significant variation was seen
when 9-cis-RA-induced transcriptional activity between
-247-cIAP2-Luc and longer cIAP2 promoter constructs
was compared. Because no obvious RAREs could be
found in the 247 bp retinoic acid responsive sequence,
we systematically mutated each putative cis-acting ele-
ment in the background of -247-cIAP2-Luc to test if
one of these response elements could mediate this
response (Fig. 3B). Site directed mutagenesis of these
response elements showed the critical importance of
two NF-B binding sites at positions -210 and -147 (m3
and m5 mutants, respectively) and one potential AP1
binding site at position -220, partially overlapping with
the NF-B binding site-1 (m2 mutant), and highlighted
the contribution of the AP1 binding site at position
-233 (m1 mutant) and the IRF-E site at position -130
(m6 mutant) to retinoid-induced promoter activity (Fig.
3B). To further reinforce these data, SK-BR-3 cells were
transiently co-transfected with the -247-cIAP2 reporter
gene and either an expression vector coding for a domi-
nant negative mutant of IBa, IBa-SR(S32A/S36A) or
an expression vector coding for a dominant negative of
c-JUN (TAM-67), to test whether 9-cis-RA inducibility
was impaired. Expression of the dominant negative
mutant of IBa totally blocked retinoid inducibility of
the cIAP2 promoter, whereas expression of TAM-67
only partially suppressed retinoid-induced cIAP2 pro-
moter activity, thus confirming the critical role of NF-
B in the induction of cIAP2 expression by 9-cis-RA
(Fig. 3C). Together, these data clearly demonstrate that
NF-B is critically involved in mediating the retinoic
acid-dependent transcriptional activation of the cIAP2
promoter and that potentially other factors, particularly
c-JUN and IRFs, contribute to the overall response.
Since mutations of NF-B binding sites resulted in a
major decrease of 9-cis-RA inducibility, we tested these
sites in electrophoretic mobility shift assays. EMSAs
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with extracts of T47D cells demonstrated that 9-cis-RA
induces the binding of a protein complex to the cIAP2
NF-B1 and NF-B3 sites. Incubation with antibodies
against p65 inhibited binding, revealing the presence of
this NF-B family member in these complexes (Fig. 4A).
Therefore, we conclude that 9-cis-RA induces the for-
mation of p65-containing complexes at the NF-B bind-
ing sites of the cIAP2 promoter.
To gain a deeper insight into the molecular mechan-
isms underlying 9-cis-RA induction of cIAP2
transcription, we performed chromatin immunoprecipi-
tation (ChIP) assays to assess the in vivo recruitment of
p65, RAR, RXRa and c-JUN to the cIAP2 promoter in
untreated and 9-cis-RA-treated T47D cells. ChIP assays
revealed that 9-cis-RA induced acetylation of histone H3
at the cIAP2 promoter, a hallmark of transcriptional
activation. In addition, we could not detect basal occu-
pancy of the cIAP2 promoter by p65, RAR or RXRa,
but significant occupancy of the promoter by these tran-
scription factors was observed after exposure of T47D
Figure 2 9-cis-RA induces the expression of cIAP2 in breast cancer cells in a cell context dependent manner. (A, B, C) Multiplex RNase
protections assays (RPAs) to monitor the effect of 9-cis-RA on the expression of death receptor, death ligands, IAP and TRAF family members in
four different breast cancer cell lines. Breast cancer cells were treated for the indicated time with 9-cis-RA at a concentration of 10-6 M. (D)
Western blot of whole cell extracts of 9-cis-RA-treated T47D cells and H3396 cells for 0, 12, 24, 48, 72 and 96 hours with anti-cIAP2. The
nonspecific signal (n. sp.) confirms equal loading. As a positive control, breast cancer cells were treated with 50 μg/ml of hTNFa for 24 and 48
hours. (E) Reversibility of 9-cis-RA-induced cIAP2 gene expression. T47D cells were treated either in the absence or presence of 1 μM 9- cis-RA
and after 3 days, total RNA was extracted. In parallel flasks, the medium was removed, and cells were washed and treated with either fresh
control medium or medium with 10-6 M of 9-cis-RA and grown for additional 3, 6 and 9 days. Media and ligands were renewed every 3 days.
RNA was isolated and analyzed by RPA as described in (A). Equal loading was confirmed by GAPDH RNA level. The images shown are from one
representative experiment performed twice with similar results.
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Figure 3 9-cis-RA activates cIAP2 transcription through NF-B response elements. (A) Illustration of the reporter constructs containing 5’-
deletion fragments of the cIAP2 upstream regulatory region. Luciferase activity in SK-BR-3 cells transiently transfected with the indicated cIAP2
reporter gene in the presence (black bars) and absence (white bars) of 9-cis-RA. The data shown represent the mean ± SD of three independent
experiments performed in duplicate. The luciferase levels were normalized with those of b-galactosidase and expressed as the induction over
the controls. (B) Transfection experiments as described in (A) but using site-specific mutants derived from -247-cIAP2 promoter as depicted (Black
triangle), the wild-type promoter (Black square) and the backbone vector pGL3 (Black diamond). After transfection, SK-BR-3 cells were treated
with different doses of 9-cis-RA, as indicated. The data shown represent the mean ± SD of three independent experiments performed in
duplicate. The luciferase levels were normalized with those of b-galactosidase and expressed as the induction over the controls. Asterisks denote
the existence of statistically significant differences between the wild-type and mutant promoter constructs. (C) SK-BR-3 cells were transiently co-
transfected with the -247- cIAP2 reporter gene and pSG5, pSG5-IBaSR(S32A/S36A) or pcDNA-TAM54 (a dominant-negative version of c-JUN)
and either untreated or treated with 9-cis-RA, as described in (B). The luciferase levels were normalized with those of b-galactosidase and
expressed as the induction over the controls. The values represent the mean ± SD of three experiments performed in duplicate. Asterisks denote
statistically significant differences against cells transfected with an empty vector.
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cells to 9-cis-RA. In contrast with the results obtained
with the cIAP2 promoter, p65 was not recruited to the
RARb gene promoter, a well-characterized retinoic acid-
responsive gene, where we were able to detect basal and
induced recruitment of RAR and RXRa (Fig. 4B, middle
panel). Whereas binding of cJUN to the cIAP2 promoter
in 9-cis-treated T47D chromatin extracts was not
observed (Fig. 4B, upper panel), strong occupancy of the
cJUN proximal promoter, used as a positive control, was
easily detected (Fig. 4B, lower panel). Interestingly, this
binding was reduced in 9-cis-RA-treated cells. Together,
these data suggest that the recruitment of NF-B factors
and retinoic-acid receptors might be responsible for 9-
cis-RA induction of cIAP2 gene transcription.
9-cis-RA pretreatment prevents apoptosis induced by
chemotherapy drugs in T47D cells: correlation with the
activation of NF-B/cIAP2 signaling pathway(s)
To explore whether cIAP2 induction may play a pro-
survival role in T47D cells, we assessed the sensitivity of
T47D and H3396 breast cancer cells pretreated with 9-
cis-RA to a diverse set of death ligands and chemother-
apy drugs. We reasoned that the induction of cIAP2 by
9-cis-RA could account for a decreased sensitivity of
T47D cells to these compounds. On the other hand, we
could anticipate that in H3396 cells, a cell-context
where 9-cis-RA did not induce cIAP2, we would not
find a decrease in the sensitivity to these drugs. First, we
investigated NF-B activation by 9-cis-RA in both breast
cancer cells systems to analyze whether the absence of
induction of cIAP2 expression in H3396 cells could be
due to a defect in the ability of retinoids to activate NF-
B signaling in these cells. To provide evidence for this
notion, we first performed EMSAs with nuclear protein
extracts from T47D cells treated with 9-cis-RA for dif-
ferent time periods. 9-cis-RA induced the binding of
protein complexes to the cIAP2 NF-B binding sites-1
and -3 in a biphasic dynamics: a strong rise in NF-B
activation is observed between 30 min and 1 h after 9-
cis-RA treatment, followed by another increment in NF-
B activation around 24-48 hours, although the latter
appears to show a much weaker binding intensity. Paral-
lel experiments in H3396 cells showed that 9-cis-RA did
not induce the binding of protein complexes to the NF-
B sites at any time tested (Fig. 5A). These data sug-
gested that the lack of induction of cIAP2 expression by
retinoids in H3396 cells might indeed be due to a defect
in the activation of NF-B in these cells.
Death of T47D and H3396 cells, in the absence or
presence of 9-cis-RA pretreatment, was examined after
exposure to various apoptogenic insults: anti-FAS,
TRAIL, etoposide, doxorubicin and camptothecin. As
observed above, the treatment with 9-cis-RA alone did
not affect viability of T47D cells. However, 9-cis-RA
pretreatment decreased sensitivity of T47D cells to
Figure 4 9-cis-RA treatment results in in vivo recruitment of p65 and retinoic-acid receptors, RAR and RXR to the cIAP2 promoter. (A)
EMSA performed with probes bearing the NF-B-1 and NF-B-3 sites of the cIAP2 promoter and nuclear extracts from T47D cells treated with 1
μM 9-cis-RA for 1 h. When indicated, antibodies directed against p65 were present in the binding assays. The images shown are from one
representative experiment performed twice with similar results. B) T47D breast cancer cells were treated as indicated in Material and Methods
and ChIPs assays were performed using antibodies against p65, RARs, RXRa, cJUN or acetyl-H3 histone. Immunoprecipitated chromatin was
analyzed by real time PCR using primers specific for the cIAP2, RARb2 and cJUN promoters. Shown are data from a representative experiment,
expressed as fold induction relative to the values obtained with immunoglobulin G (IgG) used as a negative control, which were set to 1. This
experiment was repeated three times with similar results.
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doxorubicin, etoposide and camptothecin (Fig. 5B), sug-
gesting that the activation of NF-B/cIAP2 signaling
pathway(s) by retinoids in these cells correlates with an
increase in apoptosis resistance. On the other hand, in
H3396 cells where 9-cis-RA induces neither NF-B acti-
vation nor cIAP2 expression but makes the cells enter a
fully apoptotic program, death curves showed that the
treatment with 9-cis-RA not only induced apoptosis by
itself, but also increased in an additive manner the
apoptosis in response to TRAIL, etoposide, doxorubicin
or camptothecin (Fig. 5B). Note that, 9-cis-RA treatment
augmented apoptosis mediated by the death receptor
pathway in both cell lines. These results reveal that the
activation of NF-B/cIAP2 signaling pathway(s) by reti-
noids in a given breast cancer cell apparently correlates
with the ability of these retinoids to protect cells against
chemotherapy-induced apoptosis.
We further investigated the effect of 9-cis-RA in pre-
venting etoposide-mediated apoptosis in one additional
breast cancer cell line, ZR-75-1, where the retinoid
Figure 5 9-cis-RA pretreatment prevents apoptosis induced by cancer chemotherapy insults in T47D cells, but increases
chemotherapy-induced apoptosis in H3396 cells: correlation with NF-B activity induction by 9-cis-RA. (A) EMSA performed with probes
bearing the NF-B-1 and NF-B-3 sites of the cIAP2 promoter and nuclear extracts from T47D and H3396 cells treated with 1 μM 9-cis-RA for
different times, as indicated. The images shown are from one representative experiment performed twice with similar results. (B) T47D and
H3396 cells were pretreated with or without 9-cis-RA for 30 h, followed by treatment with different doses of the indicated chemotherapeutic
agents for 72 h and death ligands for 48 h. Apoptotic cells were determined by FACS analysis after staining with propidium iodide as described
in “Materials and Methods”. The values represent the mean ± SD of three independent experiments performed in duplicate. Asterisks denote
statistically significant differences between untreated cells and cells treated with 9-cis-RA.
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upregulates cIAP2 expression and potentially NF-B
activation (Fig. 2C, left panel). ZR-75-1 cells responded
to 9-cis-RA in a similar manner to T47D cells showing
a reduction in sensitivity to etoposide upon pretreat-
ment with 9-cis-RA (see Additional file 1). These results
show that the protection against etoposide-mediated cell
death exerted by 9-cis-RA is not restricted to T47D
breast cancer cells.
cIAP2 is not critically involved in the protection of
etoposide-induced apoptosis by 9-cis-RA
Previous reports have shown that exogenous overexpres-
sion of cIAP2 can abrogate apoptosis induced by geno-
toxic anticancer drugs such as etoposide, but not death
receptor-mediated apoptosis in a NF-B null back-
ground [41]. We have observed that 9-cis-RA protection
against etoposide-mediated cell death correlates with
cIAP2-induced expression by 9-cis-RA in T47D cells.
To test whether cIAP2 has a role in this protection,
expression of cIAP2 was suppressed by using transiently
expressed siRNA. Although the cIAP2-siRNA efficiently
downregulated both basal and 9-cis-RA-induced cIAP2
protein levels when compared to a scrambled siRNA
(Fig. 6A), downregulation of cIAP2 was not sufficient to
restore sensitivity to etoposide-mediated cell death in 9-
cis-RA pretreated T47D cells (Fig. 6B). To further con-
firm the above results, we compared the level of activa-
tion of caspase-3 by western blot, as a measurement of
cell death, between T47D cells transfected with a
scrambled siRNA and T47D cells transfected with a
siRNA against cIAP2. While the levels of cleaved cas-
pase-3 were induced by etoposide and strikingly abro-
gated when cells were pretreated with 9-cis-RA in
scrambled-siRNA transfected cells, downregulation of
cIAP2 protein level did not restore the levels of cleaved
caspase-3 induced by etoposide in the presence of 9-cis-
RA (Fig. 6A). This reveals that cIAP2 is not critically
involved in the inhibition of etoposide-induced apopto-
sis in 9-cis-RA pretreated T47D cells.
Over-expression of the super-repressor of NF-B
activation, IBa-SR(S32A/S36A), abrogates protection of
etoposide induced apoptosis by 9-cis-RA
To explore whether NF-B activation may play a role in
protection of etoposide-induced apoptosis by 9-cis-RA,
we generated T47D cells stably overexpressing a consti-
tutively active form of IBa, IBa-SR(S32A/S36A). This
mutated version of IBa contains serine to alanine
mutations at residues 32 and 36, which confer resistance
to signal-induced phosphorylation and subsequent pro-
teasome-mediated degradation. Thus, NF-B dimers
remain bound to IBa-SR(S32A/S36A) in the cytosol,
and their translocation to the nucleus and the subse-
quent transcriptional regulation of their target genes is
impaired. The cDNA coding for IBa-SR(S32A/S36A)
was inserted into de pcDNA3.1 vector and after
transfection in T47D cells, a pool of neomycin-resistant
cells was isolated (T47D-IBaSR cells). To determine
the effectiveness of the super-repressor in the stable cell
line, we assessed by western blotting IBa resistance to
TNFa-induced degradation. For this purpose, whole cell
extracts were prepared from T47D-IBaSR cells and
control cells i.e. a pool of neomycin resistant cells iso-
lated after transfection of the pcDNA3.1 vector (T47D-
vector cells). As expected, IBa was degraded after 15
min treatment with TNFa in T47D-vector cells, while
degradation of IBa was not affected by TNFa treat-
ment in the case of T47D-IBaSR cells (Fig. 7A).
Furthermore, the expression of IBa-SR(S32A/S36A)
had no effect on proliferation rate of the stable cell line
Figure 6 Suppression of cIAP2 expression is not sufficient to
abrogate 9-cis-RA inhibition of etoposide-induced apoptosis in
T47D cells. (A) T47D cells were transfected with either scrambled-
siRNA or cIAP2-siRNA and pretreated with or without 9-cis-RA for 30
h, followed by treatment with etoposide 100 μM for 24 h. Cell
lysates were analyzed by western blot for the expression of cleaved
caspase-3, cIAP2 and b-actin using specific antibodies. The images
shown are from one representative experiment performed three
times with similar results. (B) T47D cells were transfected with either
scrambled-siRNA (white bars) or cIAP2-siRNA (black bars). After 24 h,
lipid-siRNA complexes were removed from media and cells were
pretreated with or without 1 μM 9-cis-RA for 30 h, followed by
treatment with etoposide 100 μM for 72 h. The percentage of
apoptotic cells was determined by FACS analysis after staining with
propidium iodide. The values represent the mean ± SD of three
experiments performed in duplicate. Asterisks denote statistically
significant differences against the corresponding untreated cells.
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in the absence of treatment (not shown). Therefore,
T47D-IBaSR cells are a good tool to determine the
involvement of the NF-B pathway in the protection of
apoptosis by 9-cis-RA.
As a further control of the efficiency of NF-B inacti-
vation, we evaluated both the basal and 9-cis-RA-
induced level of the NF-B-dependent cIAP2 mRNA
and protein in the IBa mutant cell line by real time
PCR and western blot, and found that cIAP2 levels were
specifically down-regulated when compared to control
cells (Fig. 7B-C). To evaluate the impact of IBaSR
(S32A/S36A) overexpression in 9-cis-RA protection
against etoposide-mediated apoptosis, we compared by
Western blotting, as a measurement of cell death, the
level of activation of caspase-3 between T47D-vector
cells and T47D-IBaSR cells. While the level of cleaved
caspase-3 was induced by etoposide in control cells and
strongly abrogated when cells were pretreated with 9-
cis-RA, overexpression of the IBa mutant did not
affect notably caspase-3 activation by etoposide, but
restored very significantly the activation of cleaved cas-
pase-3 by etoposide in the presence of 9-cis-RA (Fig.
7C).
We also compared the apoptosis induced by etoposide
in the presence or absence of 9-cis-RA pretreatment in
T47D-vector and T47D-IBaSR cells by propidium
iodide staining and FACS analysis. As seen in Fig. 7D,
while pretreatment with 9-cis-RA inhibits etoposide-
mediated cell death in T47D-vector cells, apoptosis was
enhanced in T47D-IBaSR cells treated with 9-cis-RA
alone, and these cells were equally sensitive to etoposide
in the presence and absence of 9-cis-RA, showing again
the important role of the NF-B pathway in the protec-
tion of 9-cis-RA against apoptosis. These data strongly
support that this protection is mediated by NF-B
dependent mechanisms.
Discussion
A complex and intricate network of signaling pathways
determines whether a cell will either proliferate, differ-
entiate, survive or die. Retinoids, due to their strong dif-
ferentiative potential, have been widely used for both
cancer therapy and cancer prevention [43]. There are
many examples in the literature of distinct cell types
whose differentiation is under the control of retinoids:
embryonal carcinoma cells, promyelocytic leukemia
cells, neuroblastoma cells, normal erythroid progenitors,
etc. [3,44-48]. In addition to differentiation induction,
retinoids are able to initiate several other programs that
may contribute to its therapeutical potential. Indeed, it
has been shown that retinoids induce apoptosis of APL
cells and blasts of APL patients through selective para-
crine action of the death ligand TRAIL [49]. In breast
cancer cells, we provide evidence that retinoic acid
Figure 7 Over-expression of the super-repressor of NF-B
activation, IBa-SR(S32A/S36A), leads to significant abrogation
of retinoic acid-mediated inhibition of etoposide-induced
apoptosis. (A) T47D-vector and T47D-IBaSR cells were untreated
or incubated for the indicated time with hTNFa (50 ng/ml). Extracts
were analyzed by western blotting with an IBa antibody. Equal
loading was confirmed with an anti-b-actin antibody. The images
shown are from one representative experiment performed three
times with similar results. (B) T47D-vector or T47D-IBaSR cells were
untreated or treated with 9-cis-RA for 48 h and expression of cIAP2
and b-actin were analysed by Reverse-Transcriptase Polymerase
Reaction and real time PCR. The values represent the mean ± SD of
three different experiments performed in duplicate. (C) T47D-vector
or T47D-IBaSR cells were pretreated with or without 9-cis-RA for
30 h, followed by treatment with etoposide 100 μM as previously
indicated. At the indicated times, cell lysates were analyzed by
western blot for the expression of cleaved caspase-3, cIAP2 and b-
actin using specific antibodies. The images shown are from one
representative experiment performed three times with similar
results. (D) T47D-vector or T47D-IBaSR cells were pretreated with
or without 9-cis-RA for 30 h, followed by treatment with etoposide
100 μM for 72 h. The percentage of apoptotic cells was determined
by FACS analysis after staining with propidium iodide. The values
represent the mean ± SD of three independent experiments
performed in duplicate. Asterisks denote the existence of statistically
significant differences between the indicated groups; N.S.: not
significant (Student’s t-test).
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induces cell growth inhibition and depending on cell-
context, promotes a sort of differentiation without
affecting viability or makes the cells enter a fully apopto-
tic program. The finding that 9-cis-RA causes differen-
tiation of T47D cells is in agreement with the previously
reported accumulation of lipid droplets in cytoplasmic
vesicles [50] and milk protein casein [51] in normal
mammary epithelial cells, and in the breast cancer cell
lines MCF7 and AU565 [52] treated with retinoids.
However, further studies are needed to determine
whether the differentiation characterized by accumula-
tion of cellular lipid depots contributes to the antiproli-
ferative effects of retinoic acid in breast cancer cells.
A circuitry of several apoptotic programs is induced in
breast cancer cells by retinoic acid. We have previously
provided evidence that retinoids promote the induction
of TRAIL not only in hematopoietic but also in breast
cancer cells [53]. In the current study, we have shown
that induction of TRAIL and FAS by retinoic acid in the
breast cancer cell line H3396 correlates with an increase
in the number of apoptotic cells. In accordance with
studies that report that TRAIL and FAS signal through
caspase-8 activation, the activity of this enzyme is
induced in H3396 cells treated with 9-cis-RA or with
exogenous TRAIL. Although additional studies will be
required to clarify the possible involvement of the
extrinsic death pathway in retinoic-induced apoptosis in
H3396 cells, activation of downstream caspases like cas-
pase-9, as well as the release of cytochrome c and
SMAC/DIABLO from the mitochondria to the cytosol
and the loss of the mitochondrial membrane potential
prove that the intrinsic pathway is dominantly involved
in retinoic acid-induced apoptosis.
Paradoxically in certain breast cancer cells, retinoic
acid induces concomitantly to TRAIL upregulation, the
activation of a gene program of apparently opposite
functionality, characterized by the induction of the anti-
apoptotic IAP family member, cIAP2, a NF-B target
gene. cIAP2 expression was significantly modulated at
the mRNA and protein levels by retinoic acid in a cell
context dependent manner. Using promoter mapping,
promoter site-directed mutagenesis, EMSAs and chro-
matin immunoprecipitation analysis we show that reti-
noic acid induces the recruitment of NF-B proteins to
NF-B binding sites in the proximal region of the cIAP2
promoter, thereby causing induction of cIAP2 expres-
sion. In agreement with our data, the induction of NF-
B proteins binding and activity by retinoic acid has
been reported in several cell systems such as neuroblas-
toma or leukemia cells [49,54,55]. Importantly, in addi-
tion to NF-B proteins, the retinoid receptors, RAR and
RXR, are also recruited in vivo to the cIAP2 promoter
upon retinoic acid treatment, despite the absence of
bona fide RARE sites in this promoter by in silico
analysis. Protein-protein interaction between p50/p65
and RXR that could contribute to stabilize the transcrip-
tional activation complex have been described [56].
Despite the finding that mutation of an AP-1 motif
decreases 9-cis-RA inducibility, we could not detect in
vivo recruitment of cJUN to the cIAP2 promoter in
response to the retinoid. Although we cannot totally dis-
miss the possibility that cJUN takes part of the tran-
scriptional complex induced by retinoic acid, other AP-1
binding factors could be recruited to the promoter.
Importantly, although our data suggest that ligand-
bound RAR/RXR may be recruited directly to the tran-
scriptional activation complex we cannot discard that, in
addition, retinoic acid induction of cIAP2 expression
proceeds via regulatory circuits, which are likely to
involve retinoic acid-target genes as well as cross-talk
with other signaling pathways. Thus, as reported for
neuroblastoma cells [57], retinoic acid could induce the
activation in breast cancer cells of the phosphatidylinosi-
tol 3-Kinase/Akt signaling pathway that finally results in
NF-B activation.
Little is known about the anti-apoptotic potential of
retinoic acid [58-61]. We provide evidence that in a cel-
lular context, present in T47D, ZR-75-1 and SK-BR-3
cells, retinoic acid markedly upregulates cIAP2 expres-
sion. Retinoic acid significantly mitigates the apoptosis
induced by chemotherapeutic agents in T47D and ZR-
75-1 cells, while it is able to increase apoptosis by these
compounds in H3396 cells where retinoic acid does not
induce cIAP2 expression. Many antiapoptotic proteins,
such as Bcl-2, Mcl-1 and Bcl-XL, have been shown to
inhibit chemotherapeutic agent-induced apoptosis in
diverse cell system models including hematopoietic and
neuroblastoma cells. Additionally, it has been shown
that the activation of genes encoding TRAF and IAP
proteins by NF-B serves to block apoptosis promoted
by different insults including chemotherapy-induced
apoptosis in different cell types [30,32,39,62]. In particu-
lar, overexpression of cIAP2 inhibits etoposide-induced
apoptosis, processing of caspase-3 and generation of cas-
pase-like protease activity in 293T cells [21]. Accord-
ingly, it has also been shown that cIAP2 overexpression
blocked etoposide-induced processing of caspase-3 and
apoptosis in HT1080 cells under NF-B-null conditions
[41]. Thus, cIAP2 emerged as a likely candidate to med-
iate the antiapoptotic effect of retinoic acid in our cell
system. To test the involvement of cIAP2 in retinoic
acid action, we performed siRNA studies to selectively
suppress cIAP2 expression. Notably however, these stu-
dies did not show sensitization of T47D cells to etopo-
side-induced apoptosis in conditions of retinoic acid
pretreatment, despite effective cIAP2 downregulation.
These findings clearly demonstrated that cIAP2 is not
necessary for retinoic acid protection of chemotherapy-
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induced apoptosis. However, we cannot rule out the
possibility that compensatory expression of other mem-
bers of the IAP family protein could supersede the
absence of cIAP2 in our system, explaining the lack of
effect of cIAP2 knockdown. Recent data also suggest
that neither cIAP1 nor cIAP2 are able to inhibit cas-
pases directly [63]. Thus, these results and ours suggest
a more complex role for cIAP2 in antiapoptosis than
previously expected. Further studies are required to
reveal the precise involvement of cIAP2 on retinoic acid
effects in breast cancer cells.
It has been reported that the NF-B signaling pathway
plays a major role in cell survival [64] and in sensitivity
of cancers to chemotherapy [40]. In accordance with
these observations, we have found that retinoic acid can
activate the NF-B signaling pathway in certain breast
cancer cells, which correlates with the induction of
resistance against apoptosis induced by cancer therapy
agents, such as etoposide, doxorubicin or camptothecin.
Furthermore, we have demonstrated that impairment of
NF-B activation results in a moderate increment of
retinoic acid-induced apoptosis and in a similar sensitiv-
ity to etoposide in the presence and absence of 9-cis-
RA. The multiplicity of mechanisms whereby NF-B
serves the antiapoptotic function is becoming increas-
ingly complex. It has been reported that NF-B
increases the expression of several antioxidant effectors,
such as glutathione cysteine synthetase, glutathione,
manganese superoxide dismutase, hemeoxygenase, ferri-
tin heavy chain and thioredoxin [65-69]. On the other
hand, retinoic acid has been shown to reduce suscept-
ibility to oxidative stress in chick embryonic neurons
[70], in PC12 cells, and in mesangial cells [58], although
the mechanism of the antioxidant effect of retinoic acid
remains unclear. Furthermore, it has been reported that
retinoic acid treatment represses ROS accumulation by
a mechanism involving NF-B in NB4 cells; in these
studies, the impairment of NF-B activation resulted in
increased ROS levels and JNK activation in retinoic trea-
ted NB4 cells [55]. Since etoposide induces marked bio-
chemical alterations characteristic of oxidative stress,
including enhanced lipid peroxidation and decreased
levels of reduced glutathione, it will be of interest to
determine the role of different antioxidant effectors in
retinoic acid protection of etoposide-induced apoptosis.
It is tempting to speculate that retinoic acid is able to
regulate the sensitivity to chemotherapeutic agents-
induced apoptosis by increasing antioxidant defense
components through NF-B proteins in certain cellular
contexts such as T47D breast cancer cells.
Conclusions
This study illustrates the multiplicity of pathways
induced by retinoids in breast cancer cells that can
cause markedly different responses depending on the
specific cellular context: retinoids can signal towards
cell death or cell survival. Moreover, the results of this
study support an important role for the NF-B pathway
in retinoic acid signaling and retinoic acid-mediated
resistance to cancer therapy-mediated apoptosis in
breast cancer cells, independently of cIAP2. Our data
support the use of NF-B pathway activation as a mar-
ker for screening that will help to develop novel reti-
noids, or retinoid-based combination therapies with
improved efficacy. Additionally, this study further vali-
dates current efforts aimed to inhibit NF-B signaling
pathways to improve clinical therapies.
Methods
Cell culture and treatment
H3396, T47D, ZR75-1 cells were cultured in RPMI or
Dulbecco in the case of SK-BR-3 cells, containing red
phenol with 10% foetal calf serum, 100 U/ml penicillin,
100 U/ml streptomycin, and 2 mM glutamine. For the
T47D cell line, medium was supplemented with 0,6 μg/
ml insulin. 9-cis-RA and BMS493 were dissolved in
ethanol and used at 1 × 10-6 M unless otherwise indi-
cated. TRAIL (Tebu), TNFa (R&D, Minneapolis, Minne-
sota), antiFAS antibody (Tebu), Doxorubicin (Tebu),
camptothecin (Sigma) and etoposide (Sigma) were used
according to the supplier’s instructions.
Measurement of apoptosis
Sub G1 cell-population was quantified by single staining
(propidium iodide, PI) according to standard proce-
dures. Briefly, the cells were trypsinized and 2,5 × 105
cells were washed with PBS 1× and incubated overnight
at 4°C in a hypotonic buffer containing propidium
iodide (0,1% Triton X-100, 0,1% sodium citrate and 50
μg/ml propidium iodide). DNA fragmentation assays
were performed using the Cell Death Detection Elisa kit
following the manufacturer’s recommendations (Roche).
This kit measures the enrichment of histone complexed
DNA fragments (mono- and oligonucleosomes) in the
cytoplasm of apoptotic cells.
Oil Red O staining
Cells, grown in coverslips, were fixed with cold 10% For-
malin Calcium Acetate for 30 min. After fixation, cover-
slips were transferred to 60% isopropanol for 1-2
minutes at room temperature (RT). Cells were stained
with freshly filtered Oil Red O for 20 min at RT and
washed in running water to remove the excess of the
staining solution, followed by counterstaining with
hematoxylin. The coverslips were then mounted in gly-
cerin jelly.
RNase protection assays
Total RNA was extracted with Trizol (Gibco BRL).
RNase protection assays were performed according to
the supplier’s instructions (Pharmingen). Routinely, 4 μg
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total RNA and 6-8 × 105 cpm of (a-32P) uridine tripho-
sphate probe sets were used and after RNase treatment,
protected probes were resolved on 5% urea-polyacryla-
mide-bis-acrylamide gels.
Subcellular fractionation
T47D cells (3 × 106 cells per condition) and H3396 cells
(2 × 106 cells) were collected in PBS, centrifuged and
resuspended in 200 μl of ice-cold fractionation buffer
(0.025% digitonin, 250 mM sucrose, 5 mM Mg Cl2, 10
mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 20
mM HEPES, pH 7.4 and protease inhibitors) and incu-
bated on ice for 10 minutes. Cell permeabilization was
determined by Trypan-blue staining. Cells were then
centrifuged at 13,000 rpm and 4°C for 2 minutes. The
supernatant containing the cytoplasmic fraction was
then isolated from the pellet containing the mitochon-
drial fraction. The pellet was resuspended in 200 μl
RIPA buffer containing 150 mM NaCl, 1% NP-40, 0.5%
deoxycholate, 0.1% SDS, 50 mM Tris HCl, pH8 and
incubated for 30 minutes on ice. Samples were centri-
fuged for 10 minutes at 13,000 rpm and 4°C. Release of
mitochondrial proteins to the cytosol was assessed by
SDS-PAGE gels and Western blotting.
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was measured by
using the fluorescent dye DiOC6 (3, 30 dihexyloxacarbo-
cyanine iodide) (Sigma) according to the manufacturer’s
instructions. Briefly, after treatment with retinoids, cells
were incubated with 50 nM of DiOC6 at 37°C during 30
minutes. Cells were then washed with PBS and trypsi-
nized. Cells were centrifuged, washed twice with PBS,
resuspended in PBS containing 2 μg/ml of propidium
iodide and analyzed by FACS.
Western blotting
Caspase -3, -8, -9, cleaved PARP (Cell Signaling), anti-
SMAC (BD Pharmingen), anti-cytochrome c (BD Phar-
Mingen) and b-actin (Santa Cruz) antibodies were used
to probe blots of extracts prepared using RIPA buffer
(20 mM Tris, pH 7.5, 25 mM b-glycerophosphate, 2
mM EDTA, 140 mM NaCl, 1% Triton X-100, 0.1% SDS,
1% sodium deoxycholate, 1 mM PMSF, 1 mM sodium
orthovanadate, 2 mM sodium pyrophosphate and pro-
tease inhibitors cocktail). cIAP2 (R&D Systems, batch
AF817 and AF8171) antibodies were used to probe blots
of extracts prepared using Triton Lysis buffer (TLB; 10
mM Tris, pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Tri-
ton X-100, 25 mM b-glycerophosphate, 1 mM sodium
orthovanadate, 2 mM sodium pyrophosphate, 10% gly-
cerol, 1 mM PMSF, and protease inhibitors cocktail).
Immune complexes were detected by chemilumines-
cence (Amersham).
Plasmids
A 1.4 kb fragment corresponding to the 5’-flanking
region of cIAP2 gene was amplified by PCR from
human genomic DNA and cloned in XhoI and NcoI of
the basic luciferase reporter plasmid pGL3-Luc. A series
of 5’deletions of this fragment were amplified by PCR
using different forward primers containing a XhoI site at
their 5’ -end and a common reverse primer containing a
NcoI site at its 5’-end. PCR-amplified DNA fragments
were digested with XhoI and NcoI restriction enzymes,
gel purified and inserted into the respective sites in
pGL3-Luc vector. Site-directed mutagenesis of the
cIAP2 promoter was performed using QuickChange
Site-Directed Mutagenesis kit (Stratagene) following
manufacturer instructions. Nucleotide sequences were
determined by automatic DNA sequencer. Information
about primer sequences is available upon request.
pSG5-IBaSR plasmid was constructed by inserting the
human cDNA coding for a constitutively activated form
of IBa containing S32A and S36A mutations from the
retroviral plasmid pLxSN-IBaSR(S32A/S36A) into
EcoRI sites of pSG5 [71].
Transfection and luciferase assays
Transfections were performed using FuGENE transfec-
tion reagent (Roche) following manufacturer instruc-
tions. Briefly, 100 ng of luciferase reporter plasmid
were transfected along with 30 ng of pCMV-b-galacto-
side and 100 ng of different expression vectors in 60-
70% confluent cells seeded in 24-well plates. 16 hours
after transfection, cells were treated for 24 h with 9
cis-retinoic acid at the indicated concentrations.
Lysates from transfected cells were analyzed for luci-
ferase and b-galactosidase activity, and data from luci-
ferase activity were normalized by b-galactosidase
activity values.
Electrophoretic mobility shift assays
Nuclear extracts of T47D cells treated with 1 μM 9-
cis-RA acid were prepared as described by Dignam et
al. [72]. Oligonucleotide probes corresponding to the
NF-B binding site-1 (sense, 5 ’-ATG-
GAAATCCCCGA-3 ’ and antisense, 5 ’-
TCGGGGATTTCCAT-3’) and NF-B binding site-3
(sense, 5’-GCTGGAGTTCCCCT-3’ and antisense, 5’-
AGGGGAACTCCAGC-3’) were radiolabeled using T4
polynucleotide kinase in the presence of (g-32 P) ATP.
Radiolabeled double strand oligonucleotides were
mixed with 10 μg of nuclear protein extracts in a final
volume of 20 μl of binding buffer (20 mM HEPES, pH
7.9, 60 mM KCl, 1 mM Mg Cl2, 20 mM EDTA, 0.5
mM dithiothreitol, 10% glycerol) containing 2 μg poly
(dI.dC). After 30 minutes of incubation at room tem-
perature, binding complexes were separated on a 5%
non-denaturating polyacrylamide gel with 0.5× TBE
buffer. The gel was vacuum dried and subjected to
autoradiography. For supershift experiments, 0.2 μg of
p65 antibody (Santa Cruz) was added to the samples
before addition of the radiolabeled oligonucleotide.
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RNA interference
T47D breast cancer cells were seeded 24 h prior to
transfection with 100 nM siGENOME SMARTpool for
cIAP2 (Dharmacon, Thermo) using DharmaFECT-1 as
transfection reagent according to manufacturer’s
instructions. After 16 h, siRNA-lipid complexes were
removed and cells were treated with 9-cis-RA for 30 h
prior to etoposide treatment.
Chromatin Immunoprecipitation
T47D breast cancer cells growing in p150 dishes were
treated with 1 μM 9-cis-RA for 48 h. Media and ligands
were renewed 45 min before chromatin extracts were
prepared. ChIP assays were performed according to a
previously described procedure [73,74]. Sonication was
performed using a Bioruptor UCD-200TM from Diage-
node (20 min, high intensity, 30 second on/off interval).
Chromatin complexes were incubated with primary rab-
bit polyclonal antibodies to acetylated H3 histone (06-
599, Upstate), RelA/p65 (06-418, Upstate), RAR (M-454,
sc-773X), RXRa (D-20, sc553), c-jun (H79, sc-1694X) or
normal rabbit serum immunoglobulins (sc-2027). Eluted
DNA from the ChIP assays were assayed directly by
real-time PCR. DNA inputs were diluted 1:100 previous
to real time PCR assay. 1 μl of template was used per 25
μl reaction, all samples were analysed in duplicate using
SYBR-green 2× PCR Master Mix (Roche) on a Strata-
gene Mx3005P real-time PCR thermal cycler. After an
initial denaturation and activation incubation of 10 min,
45 cycles of 2-step cycling were performed with an
annealing temperature of 60°C with the following pri-
mers: forward 5’-AAAGTGTATGGCGGATGGAGG-3’
and reverse 5’CGGCATTTACTGAAAGACATTTGC-3’
to amplify the cIAP2 promoter region -364/-218; for-
ward 5’-CTCTCTGGCTGTCTGCTTTTGC-3’ and
reverse 5’-GTGAACTTTCGGTGAACCCTACC-3’ to
amplify the RARE-containing RARb2 promoter region
(-166/-35); and forward 5’-GCAGCGGAGCATTACCT-
CATC-3’ and reverse primer 5’-CAGTCAACCCC-
TAAAAATAGCCC-3’ to amplify the cJUN promoter
region containing the AP1 site (-130/+31). Melting
curves were performed to verify product specificity.
Relative fold induction over IgG for each immunopreci-
pitate was assessed by analysing the change in threshold
cycle number (delta Ct) upon normalization to their
respective inputs.
Reverse-Transcriptase Polymerase Reaction
Total RNA was isolated using Tri-Reagent (Sigma) and
1 μg of RNA was used in a reverse transcription reac-
tion as instructed using iScript cDNA synthesis kit
from Bio-RAD. Quantitative PCR was performed using
equal amounts of cDNA with the following primers:
cIAP2 mRNA 5’-AGCTGAAGCTGTGTTATAT-
GAGC-3’ (forward) and 5’-ACTGTACCCTTGATTG-
TACTCCT-3’ (reverse) and b-actin mRNA 5 ’-
AACTCCATCATGAAGTGTGACG-3’ (forward) 5’-
GATCCACATCTGCTGGAAGG-3’ (reverse).
Statistical analysis
Student’s t test was performed using the Microsoft
Excell software (version 11.5.4). The statistical signifi-
cance of difference between groups was expressed by
asterisks (*, 0.01 <P < 0.05; **, 0.001 <P < 0.01; ***, P <
0.001).
Additional file 1: 9-cis-RA pretreatment prevents apoptosis induced
by etoposide in ZR-75-1 breast cancer cells. ZR-75-1 cells were
pretreated with or without 9-cis-RA for 30 h, followed by treatment with
different doses of etoposide for 72 h. Apoptotic cells were determined
by FACS analysis after staining with propidium iodide as described in
“Materials and Methods”.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1476-4598-9-15-
S1.PDF ]
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